piur tUSProject reference: 695913
Funded under :
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
A cost effective 3D tomographic ultrasound technology for vascular diagnostics
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Call for proposal:H2020-SMEINST-1-2015See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
piur imaging GmbH develops tomographic ultrasound solutions for the safe and cost-efficient image diagnostics of vascular diseases. piur’s expertise lies in medical devices, 3D imaging and image diagnostics. Each year cardiovascular disease (CVD) causes over 4 m deaths in Europe and 17.3 m deaths globally with numbers expected to grow to over 23.6 m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196 bn a year.
Ultrasound scanning imaging systems are currently the primary choice for vascular diagnostics. However, due to low sensitivity in the lower limbs, a limited field of action and poor quantification accuracy, patients are often referred for secondary scanning procedures such as computed tomography angiography, magnetic resonance angiography and catheter angiography for more detailed imaging. Referrals delay treatment, expose the patient to potential health risks and pose higher costs to healthcare providers. This presents a need to improve the rapidity and safety of the diagnosis of vascular conditions in patients to enable rapid treatment of conditions such as peripheral artery disease. There is also a need for cost effective preventative screening and surveillance to enable early intervention, for example, people at high risk of stroke.
piur imaging has developed piur tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging. This system will provide a low cost and reproducible imaging solution that will reduce the need for referrals within the vascular field and be an effective tool for preventative screening and early intervention for people with CVD.
EU contribution: EUR 50 000